XERIS BIOPHARMA HOLDINGS, INC. Finite-Lived Intangible Asset, Expected Amortization, Year One
XERIS BIOPHARMA HOLDINGS, INC. (XERS) had Finite-Lived Intangible Asset, Expected Amortization, Year One of $8.64 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths · last filed 2026-08-06
- 2026-06-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $8.64M.
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $8.64M.
- 2025-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $10.29M.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $10.29M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year One |
|---|---|
| 2026-06-30 | $8.64M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $8.64M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $10.29M 10-K · filed 2026-03-02 |
| 2025-09-30 | $10.29M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $10.29M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $10.29M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $10.84M 10-K · filed 2025-03-06 |
| 2024-09-30 | $10.84M 10-Q · filed 2024-11-08 |
| 2024-06-30 | $10.84M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $10.84M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $10.84M 10-K · filed 2024-03-06 |
| 2023-09-30 | $10.84M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $10.84M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $10.84M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $10.84M 10-K · filed 2023-03-08 |
| 2022-09-30 | $10.84M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $5.42M 10-Q · filed 2022-08-10 |
| 2022-03-31 | $8.13M 10-Q · filed 2022-05-11 |
| 2021-12-31 | $10.84M 10-K · filed 2022-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |